Merus N.V. - ADR

Name: Merus N.V. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Merus N.V. - ADR

Stock Card

$90.00

$0.00 (0.00%)

As on 02-Jan-2026 09:30EDT

Market cap

$6,826 Mln

Revenue (TTM)

$51 Mln

P/E Ratio

P/B Ratio

8.8

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Merus N.V. - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 90.00 High: 90.00

52 Week Range

Low: 33.19 High: 97.14

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-4.9
Debt to Equity

0
Book Value

$--
EPS

$-4.7
Face value

--
Shares outstanding

75,847,175

10 Years Aggregate

CFO

$-655.87 Mln

EBITDA

$-729.92 Mln

Net Profit

$-705.25 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Merus N.V. - ADR	0.0	-6.2	-4.4	114.0	79.9	38.7	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Jan-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Merus N.V. - ADR	114.0	77.8	-51.4	81.4	24.5	0.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Merus N.V. - ADR	90.0	6,826.3	51.2	-334.9	-636.8	-53.3	--	8.8
ATAI Life Sciences BV (ATAI)	7.3	2,703.6	4.5	-668.2	-15,198.8	-335.5	--	15.5
CureVac NV (CVAC)	4.7	1,049.3	510.5	193.6	-21.7	25.5	7	1.0
InflaRx N.V. - ADR	2.2	328.6	0.0	-39.1	281,529.0	-41.7	--	2.0
LAVA Therapeutics NV (LVTX)	1.7	45.8	5.0	-23.3	-442.3	-121	--	3.6
Pharvaris BV (PHVS)	35.3	2,479.6	0.0	-171.6	--	-60	--	7.4
ProQR Therapeutics N.V. - ADR	2.3	323.2	18.5	-42.3	-230.0	-65.7	--	3.5
Qiagen N.V. - ADR	43.1	9,271.6	2,100.4	409.3	23.8	11.5	22.7	2.7
Uniqure NV (QURE)	48.7	3,379.5	18.7	-252.2	-1,047.2	-96.5	--	10.6

Shareholding Pattern

View Details

About Merus N.V. - ADR

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or... non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S. Read more

CEO, President & Executive Director

Dr. Sven Ante Lundberg M.D.
CEO, President & Executive Director

Dr. Sven Ante Lundberg M.D.
Headquarters

Utrecht
Website

https://www.merus.nl

FAQs for Merus N.V. - ADR

What is the current share price of Merus NV - ADR Today?

The share price of Merus NV - ADR is $90.00 (NASDAQ) as of 02-Jan-2026 09:30 EDT. Merus NV - ADR has given a return of 79.85% in the last 3 years.

What is the current PB & PE ratio of Merus NV - ADR?

Since, TTM earnings of Merus NV - ADR is negative, P/E ratio is not available.
The P/B ratio of Merus NV - ADR is 8.81 times as on 02-Jan-2026, a 19 premium to its peers’ median range of 7.40 times.

PE & PB ratio at the end of financial year.